§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇵🇭Philippines	🇺🇸United States
Authority & dossier
Regulatory authority	FDA Philippines (CDRR)	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	—
Lead pathway (timeline & fees) — Initial Registration — Standard Review · New Drug Application — 505(b)(1)
Pathway name	Initial Registration — Standard Review	New Drug Application — 505(b)(1)
Approval timeline	365–730 days	304–365 days
Application fee	PHP 30,000	USD 4,310,002
Annual renewal	PHP 0	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	LTO holders must designate a Qualified Person (typically a registered pharmacist) responsible for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) as the contact for FDA's Pharmacovigilance Division.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	3 designations	6 designations
Examples	Facilitated Registration Pathway — Abridged & Verification Review, Emergency Use Authorisation (EUA), Conditional / Monitored Release Registration	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per FDA Circulars (aligned with ASEAN Variation Guideline) into Major Variation (FDA approval), Minor Variation (prior approval or notification) and Administrative Variation. Renewal Data Capture (RDC) modernised the renewal workflow under the eRegistration system.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	CPR is initially valid for 5 years and renewable for 5 years; renewal via Renewal Data Capture (RDC) under the modified eRegistration system, with up-to-date CMC, safety and labelling information.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	FDA's Pharmacovigilance Division coordinates national ADR reporting (the Philippines is a member of the WHO Programme for International Drug Monitoring, Uppsala). CPR holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–120 days	30–30 days
GCP standard	ICH E6(R2) GCP; FDA Philippines Good Clinical Practice guidelines and Philippine Council for Health Research and Development (PCHRD) National Ethical Guidelines	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	No	No
HTA required	Yes	No
HTA body	Health Technology Assessment Council (HTAC) under the Universal Health Care Act (RA 11223, 2019)	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

PhilippinesFDA Philippines (CDRR)
United StatesFDA

English submissions

PhilippinesYes
United StatesYes

CTD accepted

PhilippinesYes
United StatesYes

eCTD accepted

PhilippinesNo
United StatesYes

Reliance pathway

PhilippinesAvailable
United StatesNone

Reference agencies

PhilippinesFDA (US), EMA, MHRA (UK), Health Canada +4
United States—

Lead pathway (timeline & fees) — Initial Registration — Standard Review · New Drug Application — 505(b)(1)

Pathway name

PhilippinesInitial Registration — Standard Review
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Philippines365–730 days
United States304–365 days

Application fee

PhilippinesPHP 30,000
United StatesUSD 4,310,002

Annual renewal

PhilippinesPHP 0
United StatesUSD 416,734

Local representative

PhilippinesRequired
United StatesNot required

Local manufacturing

PhilippinesNot required
United StatesNot required

GMP inspection

PhilippinesRequired
United StatesRequired

MAH & local presence

Local entity required

PhilippinesYes
United StatesNo

Local responsible person

PhilippinesYes
United StatesYes

RP role

PhilippinesLTO holders must designate a Qualified Person (typically a registered pharmacist) responsible for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) as the contact for FDA's Pharmacovigilance Division.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Philippines3 designations
United States6 designations

Examples

PhilippinesFacilitated Registration Pathway — Abridged & Verification Review, Emergency Use Authorisation (EUA), Conditional / Monitored Release Registration
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

PhilippinesVariations classified per FDA Circulars (aligned with ASEAN Variation Guideline) into Major Variation (FDA approval), Minor Variation (prior approval or notification) and Administrative Variation. Renewal Data Capture (RDC) modernised the renewal workflow under the eRegistration system.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

PhilippinesCPR is initially valid for 5 years and renewable for 5 years; renewal via Renewal Data Capture (RDC) under the modified eRegistration system, with up-to-date CMC, safety and labelling information.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

PhilippinesFDA's Pharmacovigilance Division coordinates national ADR reporting (the Philippines is a member of the WHO Programme for International Drug Monitoring, Uppsala). CPR holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

PhilippinesAvailable
United StatesAvailable

Compassionate Use

PhilippinesAvailable
United StatesAvailable

Emergency Import

PhilippinesAvailable
United StatesAvailable

Parallel Import

PhilippinesNot permitted
United StatesNot permitted

Clinical trials

CTA approval

PhilippinesRequired
United StatesRequired

Ethics approval

PhilippinesYes
United StatesYes

CTA timeline

Philippines60–120 days
United States30–30 days

GCP standard

PhilippinesICH E6(R2) GCP; FDA Philippines Good Clinical Practice guidelines and Philippine Council for Health Research and Development (PCHRD) National Ethical Guidelines
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

PhilippinesRegulated
United StatesFree pricing

Reference pricing

PhilippinesNo
United StatesNo

HTA required

PhilippinesYes
United StatesNo

HTA body

PhilippinesHealth Technology Assessment Council (HTAC) under the Universal Health Care Act (RA 11223, 2019)
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding